Composition and application thereof in anti-aging aspect

Abstract

The invention relates to a composition and application thereof in anti-aging aspect. Specifically, the invention provides a composition, and the composition comprises a pseudo-ginseng extract and / or an aloe extract. The pseudo-ginseng extract and the aloe extract disclosed by the invention have an excellent anti-aging effect, and the pseudo-ginseng extract and the aloe extract have a synergistic effect in the anti-aging aspect.

Description

Technical Field

[0001] The present invention relates to the field of pharmaceutical technology, and particularly relates to a composition and its use in anti-aging. Background Art

[0002] Skin aging is a common phenomenon. Many factors such as ultraviolet radiation can cause skin aging, and the collagen content in aging skin often decreases. Collagen secreted by skin fibroblasts, such as type III collagen, plays a supporting and structural role in the skin, and can maintain the elasticity and firmness of the skin. The reduction of collagen leads to the appearance of skin relaxation and wrinkles. By supplementing collagen, the skin can be kept elastic and firm, thereby slowing down the process of skin aging and achieving the effect of beauty care. However, in the prior art, there is a lack of a product and method that can effectively resist aging. With the continuous improvement of living standards and health requirements, how to develop an anti-aging product and method has become a research hotspot today.

[0003] Therefore, there is a need in the art to develop an anti-aging product and method. Summary of the Invention

[0004] The object of the present invention is to provide a composition for anti-aging.

[0005] In the first aspect of the present invention, a composition is provided, and the composition includes notoginseng extract and / or aloe extract.

[0006] Preferably, the composition includes notoginseng extract and aloe extract.

[0007] Preferably, the extract is dry extract.

[0008] Preferably, the extract is dry extract.

[0009] Preferably, the weight ratio of the notoginseng extract to the aloe extract is 1:0.1 - 20, more preferably 1:0.1 - 15, more preferably 1:0.2 - 10, more preferably 1:0.3 - 8, more preferably 1:0.5 - 5, more preferably 1:1 - 4, more preferably 1:1.5 - 3.5, more preferably 1:2 - 3, more preferably 1:2.3 - 2.7, more preferably 1:2.5.

[0010] Preferably, the notoginseng extract is prepared by extraction with an aqueous ethanol solution.

[0011] Preferably, the notoginseng extract includes an aqueous ethanol solution extract.

[0012] Preferably, in the aqueous ethanol solution, the volume fraction of ethanol is 30-90%, preferably 50-90%, more preferably 60-80%, more preferably 65-75%, more preferably 68-72%, and most preferably 70%.

[0013] Preferably, the notoginseng extract is prepared by the following method, which includes:

[0014] (1) Extract notoginseng with an aqueous ethanol solution to obtain a notoginseng extract.

[0015] Preferably, in step (1), in the aqueous ethanol solution, the volume fraction of ethanol is 30-90%, preferably 50-90%, more preferably 60-80%, more preferably 65-75%, more preferably 68-72%, and most preferably 70%.

[0016] Preferably, in step (1), the extraction method of the aqueous ethanol solution is heating under reflux.

[0017] Preferably, in step (1), the extraction time of the aqueous ethanol solution on notoginseng is 0.5-5 h, preferably 1-3 h, more preferably 1-2 h, more preferably 1.3-1.7 h, and most preferably 1.5 h.

[0018] Preferably, in step (1), the weight ratio of the notoginseng raw material to the aqueous ethanol solution is 1:3-12, preferably 1:3-10, more preferably 1:4-8, preferably 1:5-7, preferably 1:5.5-6.5, and most preferably preferably 1:6.

[0019] Preferably, the notoginseng extract is prepared by the following method, which includes:

[0020] (1) Extract notoginseng with an aqueous ethanol solution to obtain an extract, and evaporate the extract to dryness to obtain a notoginseng extract.

[0021] Preferably, in step (1), after extracting notoginseng with an aqueous ethanol solution, filter to obtain an extract.

[0022] Preferably, the evaporation to dryness is evaporation to dryness under reduced pressure.

[0023] Preferably, the notoginseng extract is prepared by the following method, which includes:

[0024] (1) Add notoginseng to a 65-75% (v / v) aqueous ethanol solution, heat under reflux to extract, obtain an extract, and evaporate the extract to dryness to obtain a notoginseng extract.

[0025] Preferably, the notoginseng extract is prepared by the following method, which includes:

[0026] (1) Panax notoginseng is added to an aqueous ethanol solution of 70% (v / v), and extracted by heating under reflux to obtain an extract. The extract is evaporated to dryness to obtain a Panax notoginseng extract.

[0027] Preferably, the Panax notoginseng extract is prepared by the following method, which includes:

[0028] Take 200 g of Panax notoginseng, add 1200 mL of an aqueous ethanol solution of 70% (v / v), extract by heating under reflux for 1.5 h, filter, and the obtained filtrate is concentrated under reduced pressure and evaporated to dryness to obtain a Panax notoginseng extract.

[0029] Preferably, the aloe extract is prepared by the following method, which includes:

[0030] (a) Aloe is extracted with water to obtain an extract, and the extract is centrifuged to separate the supernatant;

[0031] (b) The supernatant prepared in step (a) is mixed with Sevag reagent and then centrifuged, and then the supernatant is separated. An aqueous ethanol solution is added to the supernatant, allowed to stand, and filtered to obtain an aloe extract.

[0032] Preferably, in step (a), after aloe is extracted with water, it is filtered to obtain an extract.

[0033] Preferably, in step (a), the extraction time of water on aloe is 1 - 5 h, preferably 2 - 4 h, more preferably 2.5 - 3.5 h, more preferably 2.8 - 3.2 h, and most preferably 3 h.

[0034] Preferably, in step (a), the extraction temperature of water on aloe is 30 - 100 °C, preferably 30 - 90 °C, preferably 50 - 90 °C, more preferably 60 - 80 °C, more preferably 65 - 75 °C, more preferably 68 - 72 °C, and most preferably 70 °C.

[0035] Preferably, in step (a), the weight ratio of the aloe raw material to the water is 1:3 - 12, preferably 1:3 - 10, more preferably 1:4 - 8, preferably 1:5 - 7, preferably 1:5.5 - 6.5, and most preferably preferably 1:6.

[0036] Preferably, in step (a), the centrifugation speed is 4000 - 12000 r / min, preferably 6000 - 10000 r / min, more preferably 7000 - 9000 r / min, more preferably 7500 - 8500 r / min, more preferably 7800 - 8200 r / min, and most preferably 8000 r / min.

[0037] Preferably, in the step (a), the centrifugation time is 5 - 40 min, more preferably 5 - 30 min, still more preferably 5 - 25 min, still more preferably 10 - 20 min, still more preferably 13 - 17 min, and most preferably 15 min.

[0038] Preferably, in the step (b), the supernatant prepared in the step (a) is mixed with Sevag reagent after concentration.

[0039] Preferably, the concentration multiple is 3 - 10 times, more preferably 4 - 8 times, still more preferably 5 - 7 times, still more preferably 5.5 - 6.5 times, and most preferably 6 times.

[0040] Preferably, in the step (b), the volume ratio of the concentrated solution of the supernatant prepared in the step (a) after concentration to the water in the step (a) is 1:3 - 12, more preferably 1:3 - 10, still more preferably 1:4 - 8, more preferably 1:5 - 7, more preferably 1:5.5 - 6.5, and most preferably 1:6.

[0041] Preferably, in the step (b), the volume ratio of the supernatant prepared in the step (a) to the Sevag reagent is 1 - 10:1, more preferably 1 - 8:1, still more preferably 2 - 6:1, still more preferably 3 - 5:1, still more preferably 3.5 - 4.5:1, still more preferably 3.8 - 4.2:1, and most preferably 4:1.

[0042] Preferably, in the step (b), the volume ratio of the concentrated solution of the supernatant prepared in the step (a) after concentration to the Sevag reagent is 1 - 10:1, more preferably 1 - 8:1, still more preferably 2 - 6:1, still more preferably 3 - 5:1, still more preferably 3.5 - 4.5:1, still more preferably 3.8 - 4.2:1, and most preferably 4:1.

[0043] Preferably, in the step (b), the Sevag reagent includes chloroform and n-butanol.

[0044] Preferably, in the step (b), the Sevag reagent includes a mixed solution of chloroform and n-butanol.

[0045] Preferably, the volume ratio of chloroform to n-butanol is 2 - 8:1, more preferably 3 - 7:1, still more preferably 4 - 6:1, still more preferably 4.5 - 5.5:1, and most preferably 5:1.

[0046] Preferably, the Sevag reagent can remove proteins from the extract.

[0047] Preferably, in the step (b), the mixing time is 10 - 50 min, more preferably 10 - 40 min, still more preferably 10 - 30 min, still more preferably 15 - 25 min, still more preferably 18 - 22 min, and most preferably 20 min.

[0048] Preferably, in the step (b), the mixing is thorough shaking and mixing.

[0049] Preferably, in the step (b), the rotation speed of the centrifugation is 4000 - 12000 r / min, more preferably 6000 - 10000 r / min, still more preferably 7000 - 9000 r / min, still more preferably 7500 - 8500 r / min, still more preferably 7800 - 8200 r / min, and most preferably 8000 r / min.

[0050] Preferably, in the step (b), the centrifugation time is 3 - 15 min, more preferably 3 - 10 min, still more preferably 3 - 8 min, still more preferably 4 - 6 min, still more preferably 4.5 - 5.5 min, and most preferably 5 min.

[0051] Preferably, in the step (b), in the ethanol aqueous solution, the volume fraction of ethanol is 60 - 95%, more preferably 65 - 95%, still more preferably 70 - 90%, still more preferably 75 - 85%, still more preferably 78 - 82%, and most preferably 80%.

[0052] Preferably, in the step (b), the volume ratio of the ethanol aqueous solution to the supernatant separated after the centrifugation treatment is 1 - 10:1, more preferably 1 - 8:1, still more preferably 2 - 6:1, still more preferably 3 - 5:1, still more preferably 3.5 - 4.5:1, still more preferably 3.8 - 4.2:1, and most preferably 4:1.

[0053] Preferably, in the step (b), the temperature for standing is 2 - 8°C, more preferably 2 - 6°C, still more preferably 3 - 5°C, still more preferably 3.5 - 4.5°C, and most preferably 4°C.

[0054] Preferably, in the step (b), the standing time is 5 - 25 h, more preferably 5 - 20 h, still more preferably 8 - 16 h, still more preferably 10 - 14 h, still more preferably 11 - 13 h, still more preferably 11.5 - 12.5 h, and most preferably 12 h.

[0055] Preferably, in the step (b), after standing, a precipitate appears.

[0056] Preferably, in the step (b), the precipitate after filtration is the aloe extract.

[0057] Preferably, the precipitate is dried to obtain the aloe extract.

[0058] Preferably, the aloe extract is prepared by the following method, which includes:

[0059] (a) Extract aloe with water to obtain an extract solution, and subject the extract solution to centrifugation to separate and obtain a supernatant;

[0060] (b) Mix the supernatant prepared in step (a) with Sevag reagent, then subject it to centrifugation, and then separate and obtain a supernatant. Add an ethanol aqueous solution of 75 - 85% (v / v) to the supernatant, let it stand at 2 - 6 °C, and filter to obtain the aloe extract.

[0061] Preferably, the aloe extract is prepared by the following method, which includes:

[0062] Take 200 g of aloe, add it to 1200 mL of water, stir and extract at 70 °C for 3 h, filter, centrifuge the obtained filtrate at 8000 r / min for 15 min, collect the obtained supernatant, concentrate it under reduced pressure to obtain 200 mL of concentrated solution. Mix the concentrated solution with Sevag reagent in a volume ratio of 4:1, shake well for 20 min, then centrifuge at 8000 r / min for 5 min, separate and obtain a supernatant. While stirring, add 4 times the volume of 80% (v / v) ethanol aqueous solution to the supernatant, let it stand at 4 °C for 12 h, then filter to obtain a precipitate, and dry the precipitate to obtain the aloe extract.

[0063] Preferably, the content of the notoginseng extract is 0.001 - 99.9 wt%, preferably 0.1 - 99 wt%, more preferably 1 - 99 wt%, more preferably 1 - 90 wt%, more preferably 10 - 90 wt%, more preferably 20 - 80 wt%, more preferably 30 - 70 wt%, more preferably 20 - 40 wt%, based on the weight of the composition.

[0064] Preferably, the content of the aloe extract is 0.001 - 99.9 wt%, preferably 0.1 - 99 wt%, more preferably 1 - 99 wt%, more preferably 1 - 90 wt%, more preferably 10 - 90 wt%, more preferably 20 - 80 wt%, more preferably 30 - 70 wt%, more preferably 20 - 40 wt%, based on the weight of the composition.

[0065] Preferably, the composition includes an anti - aging composition.

[0066] Preferably, the composition is a pharmaceutical composition, a food composition, a health - care product composition or a cosmetic composition.

[0067] Preferably, the composition further includes a pharmaceutically, food - wise, health - care - product - wise or cosmetically acceptable carrier.

[0068] Preferably, the dosage form of the composition is a solid preparation, a semi-solid preparation or a liquid preparation.

[0069] Preferably, the dosage form of the pharmaceutical composition, food composition or health product composition is an oral preparation.

[0070] Preferably, the dosage form of the pharmaceutical composition or cosmetic composition is a topical preparation.

[0071] Preferably, the dosage form of the pharmaceutical composition or cosmetic composition is a cream, a lotion, a solution, a spray or a patch.

[0072] Preferably, the administration object of the composition is a human.

[0073] The second aspect of the present invention provides an active ingredient combination, which includes the following components:

[0074] (i) A first active ingredient, which includes the Panax notoginseng extract; and / or

[0075] (ii) A second active ingredient, which includes the aloe extract.

[0076] Preferably, the Panax notoginseng extract is as described in the first aspect of the present invention above.

[0077] Preferably, the aloe extract is as described in the first aspect of the present invention above.

[0078] Preferably, the active ingredient combination includes an anti-aging active ingredient combination.

[0079] Preferably, the weight ratio of the Panax notoginseng extract to the aloe extract is 1:0.1 - 20, more preferably 1:0.1 - 15, more preferably 1:0.2 - 10, more preferably 1:0.3 - 8, more preferably 1:0.5 - 5, more preferably 1:1 - 4, more preferably 1:1.5 - 3.5, more preferably 1:2 - 3, more preferably 1:2.3 - 2.7, more preferably 1:2.5.

[0080] Preferably, in the active ingredient combination, at least one active ingredient is independent.

[0081] Preferably, in the active ingredient combination, the first active ingredient and the second active ingredient are independent of each other.

[0082] The third aspect of the present invention provides a medicine box, a food box, a health product box or a cosmetic box, which includes:

[0083] (A) A first preparation containing a first active ingredient, and the first active ingredient includes the Panax notoginseng extract; and / or

[0084] (B) A second preparation containing a second active ingredient, and the second active ingredient includes aloe extract.

[0085] Preferably, the notoginseng extract is as described in the first aspect of the present invention above.

[0086] Preferably, the aloe extract is as described in the first aspect of the present invention above.

[0087] Preferably, the medicine box, food box, health product box or cosmetic box includes an anti-aging medicine box, food box, health product box or cosmetic box.

[0088] Preferably, the weight ratio of the notoginseng extract to the aloe extract is 1:0.1 - 20, more preferably 1:0.1 - 15, more preferably 1:0.2 - 10, more preferably 1:0.3 - 8, more preferably 1:0.5 - 5, more preferably 1:1 - 4, more preferably 1:1.5 - 3.5, more preferably 1:2 - 3, more preferably 1:2.3 - 2.7, more preferably 1:2.5.

[0089] Preferably, the first preparation and the second preparation are independent preparations.

[0090] Preferably, the first preparation and the second preparation are combined preparations.

[0091] Preferably, the medicine box, food box, health product box or cosmetic box further includes an instruction manual.

[0092] Preferably, the instruction manual indicates that the first preparation and the second preparation are used in combination for anti-aging.

[0093] The fourth aspect of the present invention provides the use of a composition as described in the first aspect of the present invention, an active ingredient combination as described in the second aspect of the present invention, or a medicine box, food box, health product box or cosmetic box as described in the third aspect of the present invention for preparing a drug, food, health product or cosmetic for anti-aging.

[0094] Preferably, the anti-aging includes preventing and / or treating aging.

[0095] Preferably, the aging includes skin aging.

[0096] Preferably, the aging includes human aging.

[0097] Preferably, the object of anti-aging includes humans.

[0098] Preferably, the skin includes human skin.

[0099] Preferably, the aging includes aging caused by light radiation.

[0100] Preferably, the aging includes aging caused by ultraviolet radiation.

[0101] Preferably, the ultraviolet radiation includes UVA ultraviolet rays.

[0102] Preferably, the aging includes aging caused by a decrease in type III collagen.

[0103] Preferably, the anti-aging includes anti-aging by increasing the level of type III collagen.

[0104] Preferably, the level includes the content level.

[0105] Preferably, the type III collagen includes type III collagen in skin cells.

[0106] Preferably, the type III collagen includes type III collagen of skin fibroblasts.

[0107] Preferably, the skin fibroblasts include human skin fibroblasts HFF-1.

[0108] Preferably, the subjects to which the drug, food, health product or cosmetic is administered include humans.

[0109] Preferably, the dosage form of the drug, food, health product or cosmetic is a solid preparation, semi-solid preparation or liquid preparation.

[0110] Preferably, the dosage form of the drug, food or health product is an oral preparation.

[0111] Preferably, the dosage form of the drug or cosmetic is a topical preparation.

[0112] Preferably, the dosage form of the drug or cosmetic is a cream, lotion, solution, spray or patch.

[0113] The fifth aspect of the present invention provides a method for increasing the content of type III collagen in skin fibroblasts, the method comprising the steps of:

[0114] Contacting skin fibroblasts with the composition as described in the first aspect of the present invention or the active ingredient as described in the second aspect of the present invention in combination, so as to increase the content of type III collagen in skin fibroblasts.

[0115] Preferably, the skin fibroblasts include human skin fibroblasts.

[0116] Preferably, the skin fibroblasts include human skin fibroblasts HFF-1.

[0117] Preferably, the skin fibroblasts include skin fibroblasts irradiated with ultraviolet light.

[0118] Preferably, the ultraviolet light includes UVA ultraviolet light.

[0119] Preferably, the method includes non-therapeutic and non-diagnostic methods.

[0120] Preferably, the method includes an in vitro method.

[0121] Preferably, the contact includes in vitro contact.

[0122] Preferably, the contact includes contact in an in vitro culture medium.

[0123] The sixth aspect of the present invention provides an anti-aging method, the method including administering to a subject in need a composition as described in the first aspect of the present invention, an active ingredient combination as described in the second aspect of the present invention, or a medicine box, food box, health product box or cosmetic box as described in the third aspect of the present invention, so as to anti-aging.

[0124] Preferably, the subject includes a human.

[0125] Preferably, the anti-aging includes preventing and / or treating aging.

[0126] Preferably, the aging includes skin aging.

[0127] Preferably, the aging includes human aging.

[0128] Preferably, the skin includes human skin.

[0129] Preferably, the aging includes aging caused by light radiation.

[0130] Preferably, the aging includes aging caused by ultraviolet radiation.

[0131] Preferably, the ultraviolet light includes UVA ultraviolet light.

[0132] Preferably, the aging includes aging caused by a decrease in type III collagen.

[0133] Preferably, the anti-aging includes anti-aging by increasing the level of type III collagen.

[0134] Preferably, the level includes the content level.

[0135] Preferably, the type III collagen includes type III collagen in skin cells.

[0136] Preferably, the type III collagen includes type III collagen of skin fibroblasts.

[0137] Preferably, the skin fibroblasts include human skin fibroblasts HFF-1.

[0138] It should be understood that within the scope of the present invention, the above-mentioned various technical features of the present invention and the technical features specifically described below (such as in the examples) can be combined with each other to form new or preferred technical solutions. Description of the Drawings

[0139] Figure 1 is the content of COL-3 (type III collagen) in the cell lysate supernatant after treatment for each group, where p represents whether there is a significant difference compared with the model group, "*" indicates p < 0.05, indicating a significant difference; "**" indicates p < 0.01, indicating a highly significant difference. Detailed Embodiments

[0140] The present invention has developed an extract of Panax notoginseng and an extract of Aloe vera. The extract of Panax notoginseng and the extract of Aloe vera have excellent anti-aging effects, and experimental studies of the present invention show that specific dosages of the extract of Panax notoginseng and the extract of Aloe vera have excellent synergistic effects in anti-aging.

[0141] Terms

[0142] As used herein, the terms "comprising", "including" and "containing" can be used interchangeably and include not only open definitions but also semi-closed and closed definitions. The terms include "consisting of" and "substantially consisting of".

[0143] In the present invention, the term "Paris vietnamensis (Takht.) H. Li" refers to the dried rhizome of Paris vietnamensis (Takht.) H. Li.

[0144] In the present invention, the term "Panax notoginseng" refers to the dried root of Panax notoginseng (Burk.) F.H. Chen, a plant of the Araliaceae family.

[0145] In the present invention, the term "Aloe vera" refers to the juice concentrate and dried product of the leaves of Aloe barbadensis Miller, a plant of the Liliaceae family.

[0146] As used herein, the term "70% (v / v) ethanol aqueous solution" refers to an ethanol aqueous solution with an ethanol volume fraction of 70%. For example, a 70% (v / v) ethanol aqueous solution is prepared by mixing 70 mL of absolute ethanol and 30 mL of water, and so on.

[0147] As used herein, the term "COL-3" refers to type III collagen, which is Collagen Type III Protein in English.

[0148] As used herein, the term "DMEM medium" refers to Dulbecco's Modified Eagle Medium.

[0149] As used herein, the term "ELISA" refers to enzyme linked immunosorbent assay.

[0150] In the present invention, the term "prevention" refers to a method of preventing the onset of a disease and / or its attendant symptoms or protecting a subject from acquiring a disease.

[0151] In the present invention, the term "treatment" includes delaying and terminating the progression of a disease, or eliminating the disease, and does not require 100% inhibition, eradication, and reversal.

[0152] Notoginseng extract

[0153] The present invention provides a notoginseng extract, and the notoginseng extract has excellent anti-aging effects.

[0154] In a preferred embodiment of the present invention, the notoginseng extract is prepared by the following method, and the method includes:

[0155] (a) Extracting notoginseng with an aqueous ethanol solution to obtain a notoginseng extract.

[0156] Specifically, the notoginseng extract of the present invention is as described in the first aspect of the present invention above.

[0157] Aloe extract

[0158] The present invention provides an aloe extract, and the aloe extract has excellent anti-aging effects.

[0159] In a preferred embodiment of the present invention, the aloe extract is prepared by the following method, and the method includes:

[0160] (a) Extracting aloe with water to obtain an extract solution, centrifuging the extract solution, and separating to obtain a supernatant;

[0161] (b) Mixing the supernatant prepared in step (a) with Sevag reagent, centrifuging, then separating to obtain a supernatant, adding an aqueous ethanol solution to the supernatant, standing, and filtering to obtain an aloe extract.

[0162] Specifically, the aloe extract of the present invention is as described in the first aspect of the present invention above.

[0163] Use

[0164] The notoginseng extract and aloe extract of the present invention have excellent anti-aging effects, and the notoginseng extract and aloe extract of the present invention have excellent synergistic effects in anti-aging.

[0165] In a preferred embodiment of the present invention, the anti-aging includes preventing and / or treating aging.

[0166] The aging of the present invention is preferably skin aging, such as human skin aging.

[0167] In a preferred embodiment of the present invention, the aging includes aging caused by light radiation (such as ultraviolet radiation).

[0168] In a preferred embodiment of the present invention, the anti-aging includes anti-aging by increasing the level of type III collagen.

[0169] In a preferred embodiment of the present invention, the aging includes aging caused by a decrease in type III collagen.

[0170] Preferably, the type III collagen includes type III collagen in skin cells.

[0171] Preferably, the type III collagen includes type III collagen of skin fibroblasts.

[0172] Preferably, the skin fibroblasts include human skin fibroblasts HFF-1.

[0173] Composition

[0174] The present invention also provides a composition, and the composition is preferably a pharmaceutical composition, a food composition, a health product composition or a cosmetic composition. The composition of the present invention further includes a pharmaceutically, food-wise, health product-wise or cosmetically acceptable carrier.

[0175] As used herein, the term "pharmaceutically, food-wise, health product-wise or cosmetically acceptable carrier" refers to: one or more compatible solid, semi-solid, liquid or gel fillers that are suitable for human or animal use and have sufficient purity and sufficiently low toxicity.

[0176] It should be understood that in the present invention, there are no particular limitations on the carrier, and commonly used materials in the art can be selected, or it can be prepared by conventional methods, or obtained by purchasing from the market. Some examples of acceptable carriers include cellulose and its derivatives (such as methylcellulose, ethylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, etc.), gelatin, talc, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, etc.), polyols (such as propylene glycol, glycerol, sorbitol, etc.), emulsifiers (such as Tween), wetting agents (such as sodium dodecyl sulfate), buffering agents, chelating agents, thickening agents, pH regulators, transdermal enhancers, coloring agents, flavoring agents, stabilizers, antioxidants, preservatives, bacteriostatic agents, pyrogen-free water, etc.

[0177] In a preferred embodiment of the present invention, the composition of the present invention comprises Panax notoginseng extract and aloe extract.

[0178] In a preferred embodiment of the present invention, the weight ratio of the Panax notoginseng extract to the aloe extract of the present invention is 1:0.1 - 20, more preferably 1:0.1 - 15, more preferably 1:0.2 - 10, more preferably 1:0.3 - 8, more preferably 1:0.5 - 5, more preferably 1:1 - 4, more preferably 1:1.5 - 3.5, more preferably 1:2 - 3, more preferably 1:2.3 - 2.7, more preferably 1:2.5.

[0179] In the present invention, the dosage forms of the composition include (but are not limited to) solid preparations, semi-solid preparations or liquid preparations.

[0180] The pharmaceutical preparation should match the administration method. When administering, a therapeutically effective amount of the drug is administered to the desired subject (such as a human or non-human mammal). As used herein, the term "therapeutically effective amount" refers to an amount that produces a function or activity in humans and / or animals and is acceptable to humans and / or animals. Those of ordinary skill in the art should understand that the "therapeutically effective amount" may vary depending on the form of the pharmaceutical preparation, the administration route, the excipients of the drug used, the severity of the disease, and the combination with other drugs, etc., which are within the scope of the skills of a skilled physician.

[0181] The main technical effects achieved by the present invention include:

[0182] The present invention has developed a Panax notoginseng extract and an aloe extract. The Panax notoginseng extract and the aloe extract have excellent anti-aging (such as anti-skin aging) effects, and the Panax notoginseng extract and the aloe extract have excellent synergistic effects in anti-aging.

[0183] The following further elaborates the present invention in conjunction with specific embodiments. It should be understood that the following specific embodiments are based on the present technical solution and give detailed implementation manners and specific operation processes, but the protection scope of the present invention is not limited to this embodiment.

[0184] Example

[0185] COL-3 refers to type III collagen, also known as Collagen Type III Protein in English.

[0186] Example 1

[0187] This example examines the effects of different traditional Chinese medicine extracts and their combinations in anti-aging.

[0188] 1. Preparation of different traditional Chinese medicine extracts

[0189] 1.1 Preparation of Paris polyphylla extract

[0190] (1) Take 200 g of pulverized Paris polyphylla, add 1200 mL of 70% (v / v) ethanol aqueous solution, heat under reflux for 1.5 h, filter, and the obtained filtrate is concentrated under reduced pressure to obtain 200 mL of concentrated solution. Add an equal volume of petroleum ether to the concentrated solution for extraction, extract the separated aqueous layer with an equal volume of ethyl acetate, and then extract the separated aqueous layer with an equal volume of n-butanol. The separated n-butanol layer extract is concentrated under reduced pressure and evaporated to dryness to obtain Paris polyphylla extract.

[0191] 1.2 Preparation of Panax notoginseng extract

[0192] Take 200 g of pulverized Panax notoginseng, add 1200 mL of 70% (v / v) ethanol aqueous solution, heat under reflux for 1.5 h, filter, and the obtained filtrate is concentrated under reduced pressure and evaporated to dryness to obtain Panax notoginseng extract.

[0193] 1.3 Preparation of Aloe vera extract

[0194] Take 200 g of pulverized Aloe vera, add 1200 mL of water, stir and extract at 70 °C for 3 h, filter, centrifuge the obtained filtrate at 8000 r / min for 15 min, collect the supernatant, concentrate it under reduced pressure to obtain 200 ml of concentrated solution. Mix the concentrated solution with Sevag reagent (Sevag reagent is a mixture of chloroform and n-butanol, where the volume ratio of chloroform to n-butanol is 5:1) at a volume ratio of 4:1 and shake well for 20 min (i.e., remove proteins by the Sevag method), then centrifuge at 8000 r / min for 5 min, separate the supernatant, add 4 times the volume of 80% (v / v) ethanol aqueous solution to the supernatant while stirring, let it stand at 4 °C for 12 h, then filter to obtain the precipitate, and dry the precipitate to obtain Aloe vera extract.

[0195] 2. Investigation of the anti-aging effects of different traditional Chinese medicine extracts and their combinations

[0196] 2.1 Experimental methods and results

[0197] (1) Set up a blank group, a model group, experimental group A, experimental group B, experimental group C, experimental group D, experimental group E, experimental group F, experimental group G, and experimental group H. Take human skin fibroblasts HFF-1 (from the Peking Union Medical College Cell Bank) in the logarithmic growth phase in each group and inoculate the cell suspension on a multi-well cell culture plate at a cell density of 2×10 6 cells / mL. Add 1 mL of the cell suspension to each well. After culturing overnight at 37°C and 5% CO2, aspirate the supernatant, and then add 1 mL of the following drugs with the same volume to the wells of each group for treatment:

[0198] Blank group: DMEM medium;

[0199] Model group: DMEM medium;

[0200] Experimental group A: A dispersion of Paris polyphylla extract in DMEM medium, where the concentration of Paris polyphylla extract is 1.25 μg / mL;

[0201] Experimental group B: A dispersion of Panax notoginseng extract in DMEM medium, where the concentration of Panax notoginseng extract is 0.5 mg / mL;

[0202] Experimental group C: A dispersion of Aloe vera extract in DMEM medium, where the concentration of Aloe vera extract is 2.5 mg / mL;

[0203] Experimental group D: A dispersion of Paris polyphylla extract and Panax notoginseng extract in DMEM medium, where the concentration of Paris polyphylla extract is 1.25 μg / mL and the concentration of Panax notoginseng extract is 0.5 mg / mL;

[0204] Experimental group E: A dispersion of Paris polyphylla extract, Panax notoginseng extract, and Aloe vera extract in DMEM medium, where the concentration of Paris polyphylla extract is 1.25 μg / mL, the concentration of Panax notoginseng extract is 0.5 mg / mL, and the concentration of Aloe vera extract is 2.5 mg / mL;

[0205] Experimental group F: A dispersion of Paris polyphylla extract, Panax notoginseng extract, and Aloe vera extract in DMEM medium, where the concentration of Paris polyphylla extract is 1.25 μg / mL, the concentration of Panax notoginseng extract is 0.05 mg / mL, and the concentration of Aloe vera extract is 2.5 mg / mL;

[0206] Experimental group G: A dispersion of Paris polyphylla extract, Panax notoginseng extract, and Aloe vera extract in DMEM medium, where the concentration of Paris polyphylla extract is 1.25 μg / mL, the concentration of Panax notoginseng extract is 0.05 mg / mL, and the concentration of Aloe vera extract is 1.25 mg / mL;

[0207] Experimental group H: DMEM medium dispersion of notoginseng extract and aloe extract, wherein the concentration of notoginseng extract is 0.5 mg / mL and the concentration of aloe extract is 1.25 mg / mL;

[0208] Each group was repeated 3 times. After adding drugs to each group, they were placed in an incubator at 37 °C and 5% CO2 for 6 h. Then, except for the blank group, the other groups were all stimulated with the same UVA ultraviolet light (9 J / cm 2 ). After the ultraviolet light stimulation treatment was completed, each group was cultured for another 24 h. The culture medium in each well of each group was removed, washed once with PBS 7.4 buffer, and then 400 μL of cell lysate (prepared according to the ratio of RIPA:PMSF of 100:1) was added to each well of each group. The mixture was pipetted several times to avoid the generation of bubbles as much as possible, and then centrifuged at 10,000 r / min and 4 °C for 5 min. The supernatant was taken to obtain the cell lysate supernatant of each group. An ELISA kit (Cloud-Clone crop) was used to detect the content of COL-3 (type III collagen) in the cell lysate supernatant of each group. The content of COL-3 (type III collagen) in the cell lysate supernatant of each group was as Figure 1 shown in Table 1.

[0209] Table 1 Content of COL-3 (type III collagen) in the cell lysate supernatant of each group after treatment (M±SD)

[0210]

[0211] Note: Except for the blank group, the other groups were all stimulated with the same UVA ultraviolet light (9 J / cm 2 ).

[0212] From Figure 1 Table 1, it can be seen that compared with the model group, the paris polyphylla extract, notoginseng extract, and aloe extract prepared in Example 1 of the present invention can effectively increase the content of type III collagen in skin fibroblasts, thus having excellent anti-skin aging effects. In particular, compared with the increase in the content of type III collagen in skin fibroblasts by the single notoginseng extract and aloe extract in experimental group B and experimental group C, the combination of the specific dosages of notoginseng extract and aloe extract in experimental group H has a synergistic effect in increasing the content of type III collagen in skin fibroblasts. Therefore, the combination of the specific dosages of notoginseng extract and aloe extract in experimental group H has a synergistic effect in anti-skin aging, thus significantly improving the anti-aging effect.

[0213] The above are only the preferred embodiments of the present application and are not intended to limit the present application. For those skilled in the art, various modifications and variations can be made to the present application. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present application shall be included within the protection scope of the present application.

Claims

1. A composition, characterized in that, The described composition comprises notoginseng extract and / or aloe extract.

2. The composition according to claim 1, characterized in that, The weight ratio of the notoginseng extract to the aloe extract is 1:0.1 - 20, more preferably 1:0.1 - 15, more preferably 1:0.2 - 10, more preferably 1:0.3 - 8, more preferably 1:0.5 - 5, more preferably 1:1 - 4, more preferably 1:1.5 - 3.5, more preferably 1:2 - 3, more preferably 1:2.3 - 2.7, more preferably 1:2.

5.

3. The composition according to claim 1, wherein The notoginseng extract is prepared by the following method, which includes: (1) Extracting notoginseng with an ethanol aqueous solution to obtain the notoginseng extract; The aloe extract is prepared by the following method, which includes: (a) Extracting aloe with water to obtain an extract solution, and subjecting the extract solution to centrifugation to separate and obtain a supernatant; (b) Mixing the supernatant prepared in step (a) with Sevag reagent, subjecting the mixture to centrifugation, then separating to obtain a supernatant, adding an ethanol aqueous solution to the supernatant, allowing it to stand, and filtering to obtain the aloe extract.

4. The composition according to claim 1, characterized in that, The notoginseng extract is prepared by the following method, which includes: (1) Adding notoginseng to a 65 - 75% (v / v) ethanol aqueous solution, heating under reflux for extraction to obtain an extract solution, and evaporating the extract solution to dryness to obtain the notoginseng extract; The aloe extract is prepared by the following method, which includes: (a) Extracting aloe with water to obtain an extract solution, and subjecting the extract solution to centrifugation to separate and obtain a supernatant; (b) Mixing the supernatant prepared in step (a) with Sevag reagent, subjecting the mixture to centrifugation, then separating to obtain a supernatant, adding a 75 - 85% (v / v) ethanol aqueous solution to the supernatant, allowing it to stand at 2 - 6°C, and filtering to obtain the aloe extract.

5. An active ingredient combination, characterized in that, The active ingredient combination comprises the following components: (i) A first active ingredient, which includes notoginseng extract; and / or (ii) A second active ingredient, which includes aloe extract.

6. A medicine box, food box, health product box or cosmetic box, characterized in that, The medicine box, food box, health product box or cosmetic box comprises: (A) A first preparation containing a first active ingredient, which includes notoginseng extract; and / or (B) A second preparation containing a second active ingredient, which includes aloe extract.

7. The combination of active ingredients according to claim 5 or the box, food box, health care product box or cosmetic box according to claim 6, characterized in that, The notoginseng extract and the aloe extract are as described in claim 3 or 4; The weight ratio of the notoginseng extract to the aloe extract is 1:0.1 - 20, more preferably 1:0.1 - 15, more preferably 1:0.2 - 10, more preferably 1:0.3 - 8, more preferably 1:0.5 - 5, more preferably 1:1 - 4, more preferably 1:1.5 - 3.5, more preferably 1:2 - 3, more preferably 1:2.3 - 2.7, more preferably 1:2.

5.

8. Use of a composition as claimed in claim 1, an active ingredient combination as claimed in claim 5, or a medicine box, food box, health care product box or cosmetic box as claimed in claim 6, characterized in that For preparing a drug, food, health product or cosmetic, which is used for anti - aging.

9. The use according to claim 8, wherein The aging includes aging caused by ultraviolet radiation.

10. A method for increasing the content of type III collagen in skin fibroblasts, characterized in that, The method includes the steps: Contact skin fibroblasts with the composition as described in claim 1 or the active ingredient as described in claim 5, thereby increasing the content of type III collagen in the skin fibroblasts.

Images